CLAYS PRACTICE — All Prescriptions & Medications — Page 13

Practice Code: L82051 | ST. AUSTELL, PL26 8JF

Showing results 601-650 of 716

MedicationItems (12m) ↓QuantityCostvs National
Acamprosate calcium161,722£185-54.1% ▼
Dantrolene sodium162,116£318-11.3% ▼
Apraclonidine161,374£5.5K+27.0% ▲
Acetic acid1680£74+38.1% ▲
1635£893+22.4% ▲
1628£505+135.2% ▲
161,580£5.1K-57.4% ▼
16690£1.0K-2.0% ▼
Mebeverine hydrochloride compound preparations15860£749+32.7% ▲
Naftidrofuryl oxalate151,260£148-54.0% ▼
Cilostazol151,680£1.0K+8.1% ▲
Pericyazine15840£346-86.4% ▼
Pimozide15202£73+209.4% ▲
Doxepin151,260£4.2K+15.4% ▲
Rotigotine15504£2.6K-44.4% ▼
Insulin detemir1575£630-80.8% ▼
Estradiol valerate15644£54-23.2% ▼
Tibolone151,092£105-51.0% ▼
RtS 1.4 - 2 kcal/g dessert style (milk based) (0913011)1549.0K£879-60.7% ▼
Tizanidine hydrochloride154,040£171-43.4% ▼
Liquid paraffin157,500£72+116.2% ▲
Glycopyrronium bromide15111£200-37.1% ▼
1528£285+126.7% ▲
Propafenone hydrochloride141,568£147+29.3% ▲
Valsartan/amlodipine14392£353+27.6% ▲
Prasugrel14406£59-55.5% ▼
Umeclidinium bromide1414£364-77.3% ▼
Daridorexant14420£559+7.1% ▲
Oxycodone hydrochloride/naloxone hydrochloride142,226£1.7K-19.3% ▼
Entacapone141,680£343-8.2% ▼
Glibenclamide14784£207+187.9% ▲
Saxagliptin14392£420-58.1% ▼
Denosumab1414£2.5K-48.6% ▼
Mycophenolic sodium14513£635+43.5% ▲
Lanreotide1414£13.1K+51.8% ▲
Pyridostigmine bromide142,800£223-18.2% ▼
Fusidic acid1480£319+35.5% ▲
Ketotifen fumarate141,020£210+50.5% ▲
Timolol and brimonidine14110£310-0.2% vs avg
Cocois141,060£185+2.0% ▲
1421£132-60.8% ▼
14100£171+52.0% ▲
142,070£274-37.4% ▼
14840£3.8K+123.9% ▲
14480£919+37.4% ▲
14220£1.5K+37.8% ▲
Captopril13728£257-10.2% ▼
Sulpiride13728£61-51.5% ▼
Hyoscine hydrobromide13776£118-61.9% ▼
Rufinamide1310.6K£1.9K-24.3% ▼
← Back to CLAYS PRACTICE
Data sourced from NHSBSA English Prescribing Dataset, CQC, and GP Patient Survey. Prescribing data does not indicate quality of care. Higher prescribing rates may reflect patient demographics. Always consult your GP for medical advice.